At a glance
ClinicalIndex Comparison RecordN/ACompleted· 137 enrolled
Drug / intervention
Halt Proceduredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Halt System for Laparoscopic Treatment of Symptomatic Uterine Fibroids With Radiofrequency Ablation
In Brief
A clinical study evaluating Halt Procedure for Uterine Fibroids and Uterine Myomas. Completed, enrolled 137 participants across 11 sites in 3 countries.
Detailed Summary
The purpose of this study is to demonstrate the safety and effectiveness of radiofrequency ablation (RFA) using the Halt System for the treatment of patients with symptomatic uterine fibroids.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUterine Fibroids, Uterine Myomas
CountriesGuatemala, Mexico, United States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedApr 2009
Primary CompletionJan 2012
Study CompletionMar 2014
TodayJul 2026
First PostedApr 2, 2009
Enrollment StartMar 1, 2009
Primary CompletionJan 1, 2012
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.3 years ago
Interventions
Halt Proceduredevice
The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.